作者@article {jannP2.268 ={斯特凡诺jann Raffaella法齐奥和达里奥Cocito乔凡尼安托尼尼安吉洛Schenone和安东尼奥Toscano Gerolama Marfia路易莎·德·托尼Franceschini和安娜Mazzeo埃利奥•Agostoni}, title ={大剂量静脉注射免疫球蛋白是有效的痛苦的糖尿病多神经病抵抗常规治疗。结果双盲、随机、安慰剂对照、多中心试验。体积(P2.268)} ={86} ={16}补充数量,elocation-id = {P2.268} ={2016},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:评估大剂量静脉注射免疫球蛋白的疗效和安全性(丙种球蛋白)疼痛疗法在治疗抗糖尿病痛苦的多神经病。首页背景:过度的促炎细胞因子参与了神经性疼痛的发病机制。设计/方法:随机、双盲、安慰剂对照、多中心试验,包括糖尿病患者痛苦多神经病耐抗抑郁药和atiepileptics单独或结合并报告基线疼痛的严重程度超过60个单位(毫米)血管在招生规模。结果:26糖尿病患者痛苦多神经病根据多伦多糖尿病性神经病专家小组和抵抗常规疗法被录取,随访12周。11个病人IVIg手臂和12例安慰剂手臂完成这项研究。没有明显差异有关年龄、性别和疼痛程度。丙种球蛋白组的疼痛强度的平均值从基线值的48.4降至87.3毫米的47.5和4周后,第一周在安慰剂组一周后改变了从92.9到75.8,85.8后4周(p = 0.0001)。最后研究疼痛严重程度患者的丙种球蛋白的手臂是54.1而在安慰剂组为86.7 (p = 0.001)。 The mean Neuropathic Pain Symptom Inventory (NPSI) total score in the IVIg group dropped from 86 at baseline to 50 after one week and to 40 after 4 weeks while in the placebo group changed from 89 to 80 and then to 86 (p=0.000001 comparing baseline and the fourth week in the 2 groups). The therapy was well tolerated without significant side effects along the follow up. Conclusions: The present study confirms previous data concerning a significant pain relief with IVIg in diabetic patients with a painful neuropathy resistant to conventional treatments.Disclosure: Dr. Jann has received personal compensation for activities with Grifols, CLS Behring, and Biofutura Pharma. Dr. Fazio has nothing to disclose. Dr. Cocito has received personal compensation for activities with Baxter, Italy and CSL Behring, Switzerland as a speaker. Dr. Antonini has nothing to disclose. Dr. Schenone has nothing to disclose. Dr. Toscano has nothing to disclose. Dr. Marfia has nothing to disclose. Dr. De Toni Franceschini has nothing to disclose. Dr. Mazzeo has nothing to disclose. Dr. Agostoni has nothing to disclose.Sunday, April 17 2016, 8:30 am-5:30 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/86/16_Supplement/P2.268}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }